Companies › Arvinas
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ARV-806 KRAS G12D degrader (targeted protein degradation) | KRAS | Phase 1 | KRAS G12D Mutation | Nov 2026 |
| ARV-393 Protein degrader (PROTAC) | – | Phase 1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Mar 2028 |
| ARV-6723 Immune system activator for cancer cell recognition and destruction | – | Phase 1 | Advanced Solid Tumor | Mar 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07023731 | ARV-806 | Phase 1 | KRAS G12D Mutation | Oncology | Nov 2026 |
| NCT06393738 | ARV-393 | Phase 1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Oncology | Mar 2028 |
| NCT07749586 | ARV-6723 | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2031 |
Cash and short-term investments of $558m on 2026-09-30; operating cash outflow about $172m a year; runway about 39 months at that burn, to Dec 2029
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.